Drug‐Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk Assessment May Require Endogenous Biomarker‐Informed Approach-Reference-Cited by-同舟云学术

Drug‐Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk Assessment May Require Endogenous Biomarker‐Informed Approach

Published:2020-11-13 Issue:4 Volume:110 Page:855-859
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Mathialagan Sumathy¹,Feng Bo¹,Rodrigues A. David¹,Varma Manthena V. S.¹

Affiliation:

1. Pharmacokinetics, Dynamics, and Metabolism, Medicine Design Worldwide R&D Pfizer Inc. Groton Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2089

Reference10 articles.

1. European Medicines Agency (EMA).Guideline on the investigation of drug interactions. Committee for Human Medicinal Products (CHMP) London UK (2012).

2. US Food and Drug Administration (FDA).In Vitro Metabolism‐ and Transporter‐Mediated Drug‐Drug Interaction Studies Guidance for Industry.Center for Drug Evaluation and Research (CDER) Silver Spring MD(2020) .

3. ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision

4. Transporters affecting biochemical test results: Creatinine-drug interactions

5. Evaluation of Renal Transporter Inhibition Using Creatinine as a Substrate In Vitro to Assess the Clinical Risk of Elevated Serum Creatinine

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of Inhibitory Activity against the MATE1 Transporter via Combined Fingerprint- and Physics-Based Machine Learning Models;Journal of Chemical Information and Modeling;2024-09-10

2. Drug Interactions: Mechanisms, Assessment and Management Strategies;Journal of Young Pharmacists;2024-08-23

3. Expanding Role of Endogenous Biomarkers for Assessment of Transporter Activity in Drug Development: Current Applications and Future Horizon;Pharmaceutics;2024-06-25

4. Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug–Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective;Clinical Pharmacokinetics;2024-06

5. Use of a Double-Transfected System to Predict hOCT2/hMATE1-Mediated Renal Drug–Drug Interactions;Drug Metabolism and Disposition;2024-02-07